Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 21

Trial Status

Recruiting1
Other1

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT07027124Phase 2Recruiting
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
High-risk Prostate CancerProstate Cancer
PrincipalinvestigatorStart date: 2026-05-21
NCT04761107Active Not Recruiting
Impact of COVID-19 on GU Disease
Benign Urologic ConditionsCOVID-19 InfectionGenitourinary Cancer
PrincipalinvestigatorStart date: 2021-02-18

Research Network

Collaboration Network

3 collaborators·3 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Dimple Chakravarty, PhD

Icahn School of Medicine at Mount Sinai

Similar
2 trials

Shared therapeutic areas:

Benign Urologic ConditionsCOVID-19 InfectionGenitourinary Cancer+2 more

Worked with same sponsors:

BayerIcahn School of Medicine at Mount Sinai+1 more
Collaborated on 2 trials
Similarity Score58%

Sujit S Nair, PhD

Icahn School of Medicine at Mount Sinai

Moderately Similar
1 trials

Shared therapeutic areas:

Benign Urologic ConditionsCOVID-19 InfectionGenitourinary Cancer

Worked with same sponsors:

Icahn School of Medicine at Mount Sinai
Collaborated on 1 trial
Similarity Score34%

Rahul Aggarwal, MD

University of California, San Francisco

Related
22 trials

Shared therapeutic areas:

Prostate CancerGenitourinary Cancer

Worked with same sponsors:

Merck Sharp & Dohme LLC
Similarity Score12%

Kevin Volpp, MD, PhD

University of Pennsylvania

Related
12 trials

Shared therapeutic areas:

Prostate Cancer
Similarity Score6%

Dong-Xin Wang, MD, PhD

Peking University First Hospital

Related
74 trials

Shared therapeutic areas:

Prostate Cancer
Similarity Score6%

Neha sharma, PhD

Warwick Research Services

Related
11 trials

Shared therapeutic areas:

Prostate Cancer
Similarity Score6%

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

Related
32 trials

Shared therapeutic areas:

Genitourinary Cancer
Similarity Score6%

Zhaohui Zhu, MD

Peking Union Medical College Hospital

Related
19 trials

Shared therapeutic areas:

Prostate Cancer
Similarity Score6%

Stanislaw R. Burzynski, MD, PhD

Burzynski Research Institute

Related
62 trials

Shared therapeutic areas:

Prostate Cancer
Similarity Score6%

David Hui, MD

M.D. Anderson Cancer Center

Related
13 trials

Shared therapeutic areas:

COVID-19 Infection
Similarity Score6%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT07027124Phase 2PrincipalInvestigator

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

High-risk Prostate CancerProstate Cancer
Recruiting
NCT04761107PrincipalInvestigator

Impact of COVID-19 on GU Disease

Benign Urologic ConditionsCOVID-19 InfectionGenitourinary Cancer
Active Not Recruiting

All 2 trials loaded